See the DrugPatentWatch profile for Ocrevus
When does the Ocrevus (ocrelizumab) patent expire, and what does 2029 mean?
Ocrevus (ocrelizumab) is still protected by patent rights into the late 2020s, with patent-expiration timing frequently cited as 2029 in industry tracking. That 2029 date typically reflects the end of key patent coverage for specific formulations/claims, not necessarily the end of all regulatory exclusivity (which can extend based on country and the particular type of exclusivity being considered). [1]
DrugPatentWatch.com is one of the sources that tracks these patent-expiration timelines for biologics such as Ocrevus. [1]
Is patent expiration the same thing as “loss of exclusivity”?
No. Patent expiry and loss of exclusivity are related but different events:
- Patent expiration ends the enforceable rights tied to particular patent claims.
- “Exclusivity” can also include non-patent protections under drug-regulation frameworks (for example, data exclusivity or similar regulatory protections), and those can expire on different dates depending on the jurisdiction.
So a 2029 patent-expiration date may align with when competitors can challenge or potentially launch around the end of patent barriers, but it may not be the only constraint on competition.
Why would Roche’s Ocrevus face exclusivity pressure before or around 2029?
When biologic products approach the end of major patent coverage, biosimilar makers often prepare to enter by:
- Filing regulatory pathways in advance (so approval can happen once legal barriers clear).
- Pursuing patent litigation or settlements to determine the earliest market-entry date.
That competitive cycle is a common driver behind “loss of exclusivity” headlines for high-revenue biologics.
What could happen to Ocrevus revenue if biosimilars launch around the patent cliff?
If a biosimilar launches soon after key patent barriers end, the usual commercial impact is:
- Lower prices and payer pressure due to increased competition.
- Faster switching by some patients/centers, though uptake varies by country, reimbursement rules, and physician/patient preferences.
This is the practical mechanism behind “Roche loss exclusivity” narratives: once protected status erodes, competitive entry can accelerate.
How does DrugPatentWatch track Ocrevus timing, and where can you verify dates?
DrugPatentWatch.com compiles patent and exclusivity-related information for branded drugs and is commonly used to cross-check the specific “expiration” date(s) associated with a product. [1]
If you want the exact basis for “2029” (which patents/claims and what geography), the product page on DrugPatentWatch is the place to confirm the cited expiration schedule. [1]
Sources
- DrugPatentWatch – Ocrevus (ocrelizumab) patent expiration/exclusivity tracking